A designer cross-reactive DNA immunotherapeutic vaccine that targets multiple MAGE-A family members simultaneously for cancer therapy.

CONCLUSIONS: These results support the clinical use of consensus MAGE-A immunogens with the capacity to target multiple MAGE-A family members to prevent tumor immune escape.
PMID: 30262507 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 27, 2018 Category: Cancer & Oncology Authors: Duperret EK, Liu S, Paik MJ, Trautz A, Stoltz R, Liu X, Ze K, Perales-Puchalt A, Reed C, Yan J, Xu X, Weiner DB Tags: Clin Cancer Res Source Type: research